Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncodesign SA

www.oncodesign.com

Latest From Oncodesign SA

Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace

J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.

BioPharmaceutical Deals

Mouse Avatars: Innovative Approach Holds Promise For Personalizing Cancer Treatment

Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.

Medical Device Innovation

Deals Shaping The Medical Industry, January 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November through December 2013

BioPharmaceutical Medical Device

Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration

Two CEOs describe their approach to virtual partnerships, corporate renewal, and active risk management. Plus, more conventional divestment and M&A deals from Novartis and Grifols and Roche and immatics.

BioPharmaceutical France
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
    • Transgenics
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Oncodesign SA
  • Senior Management
  • Philippe Genne, PhD, Pres. & CEO
    Jan Hoflack, PhD, CSO
    Jonathan Ewing, Dir., Bus. Dev.
  • Contact Info
  • Oncodesign SA
    Phone: 380 78 8260
    20 Rue Jean Mazen
    P.O. Box 27627 Dijon, Bourgogne, 21076
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register